Overview
- The IGeL‑Monitor review released June 18 found that existing research does not show a clear clinical benefit of osteopathic treatment for non‑specific lower back pain and identified only three reviews and two trials as relevant out of about 250 papers screened.
- The largest and highest‑quality trials cited in the report showed no convincing advantage of osteopathy over sham or placebo treatments, while the review also found no clear signals of patient harm.
- Experts are divided on the policy response: some, including physiotherapy researcher Daniel Belavy, say statutory and private insurers should not subsidize osteopathy based on current evidence, while others call the report an evidence gap that requires publicly funded, industry‑independent trials.
- Osteopathy is a widely used, mainly self‑paid service in Germany, generates significant income for practitioners and schools, and currently lacks a uniform state‑regulated training standard or protected professional title, raising questions about regulation and quality control.
- Practical next steps proposed include redirecting some osteopathy revenues into large, high‑quality trials and clearer legal rules for training and title protection, and policymakers and insurers will be watched for reimbursement or research‑funding decisions.